摘要
目的观察吉西他滨联合奥沙利铂治疗复发性或难治性非霍奇金淋巴瘤（NHL）的临床疗效。方法39例复发或难治性NHL患者，应用吉西他滨和奥沙利铂联合化疗3个周期以上后评价其疗效、不良反应，检测其血清乳酸脱氢酶（LDH）在治疗前后的浓度变化，并对患者进行随访。结果39例患者中，完全缓解者11例，占28．21％；部分缓解者16例，占41．03％；无进展者7例，占17．95％；进展者5例，占12．82％；总有效率为69．23％。结论吉西他滨和奥沙利铂联合化疗治疗复发性或难治性NHL患者安全有效。
Objective To analyze the clinical efficacy of gemcitabine plus oxaliplatin in treatment of relapsed or refractory non-Hodgkin＇s lymphoma（NHL）. Methods 39 cases with relapsed or refractory NHL were treated by gemcitabine and oxaliplatin combination chemotherapy. After three cycles, its efficacy and adverse reactions were observed. Serum lactate dehydrogenase（LDH） concentration was detected before and after treatment and all the Fatients were followed up. Results The rate CR was l leases （28. 1% ）, PR 16cases （41.03%）, NC 7cases （ 17.95% ） ,PD 5cases（ 12. 82% ）. The total response rate（ CR ＋ PR） was 69.23%. Conclusion Gemcitabine and oxaliplatin combination chemotherapy in treatment of patients with relapsed or refractory NHL was safe and effective.
出处
《中国基层医药》
CAS
2011年第17期2321-2322,共2页
Chinese Journal of Primary Medicine and Pharmacy
